Skip to main content

What the label lists and what reports show

Esmolol side effects

Esmolol's FDA label: “Most common adverse reactions (incidence >10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or …” FAERS holds 265 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is cardiac arrest (21 reports).

  • Generic listed

Check it at the source: the esmolol FDA label on DailyMed (effective March 14, 2025, Baxter Healthcare Company); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

Most common adverse reactions (incidence >10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Table 3. Clinical Trial Adverse Reactions (Frequency ≥3%)

This table is printed in the Esmolol Hydrochloride in Water label published by WG Critical Care, LLC of May 31, 2024; the label quoted above does not print one.

Preferred MedDRA TermFrequency
Hypotension* Asymptomatic hypotension Symptomatic hypotension (hyperhidrosis, dizziness)25%
Infusion site reactions (inflammation and induration)8%
Nausea7%
Dizziness3%

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued

Most common adverse reactions (incidence >10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The following adverse reaction rates are based on use of BREVIBLOC (Esmolol Hydrochloride) injection in clinical trials involving 369 patients with supraventricular tachycardia and over 600 intraoperative and postoperative patients enrolled in clinical trials. Most adverse effects observed in controlled clinical trial settings have been mild and transient. The most important and common adverse effect has been hypotension [see Warnings and Precautions (5.1) ]. Deaths have been reported in post-marketing experience occurring during complex clinical states where BREVIBLOC injection was presumably being used simply to control ventricular rate [see Warnings and Precautions (5.5) ].

Source: FDA drug label, Baxter Healthcare Company, effective March 14, 2025 (SPL set 595cc3d5-1306-4828-aefa-5595219ffd62), via openFDA; the full label on DailyMed

What do FAERS reports show?

265 reports list esmolol among the medicines taken, each a report of something that happened, not proof the medicine caused it; 47 are coded as a death and 93 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 18 reactions below, 4 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

The 25 most reported reactions

  • Drug Ineffective (a use or a product term, not a reaction)36
  • Cardiac Arrest (named in the label)21
  • Hypotension (named in the label)19
  • Bradycardia (named in the label)17
  • Product Use Issue (a use or a product term, not a reaction)15
  • Product Use In Unapproved Indication (a use or a product term, not a reaction)12
  • Renal Failure11
  • Hypertension (a use or a product term, not a reaction)9
  • Ventricular Fibrillation9
  • Atrial Fibrillation (a use or a product term, not a reaction)8
  • Death (an outcome recorded in the report)8
  • Hepatotoxicity8
  • Hyperbilirubinaemia8
  • Pulmonary Oedema8
  • Pyrexia8
  • Respiratory Failure8
  • Acute Kidney Injury7
  • Condition Aggravated (a use or a product term, not a reaction)7
  • Multi-Organ Failure7
  • Respiratory Arrest7
  • Anxiety (named in the label)6
  • Aspartate Aminotransferase Increased6
  • Blood Pressure Decreased6
  • Cardiogenic Shock6
  • Cerebrovascular Accident6

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Esmolol: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions